Brian Orelli, Ph.D. Articles

•   RSS Feed
• View Profile

Last 50 articles...

• Bigger, Better, Faster (but Behind)
• Coagulating More Revenue
• 2 Drug Approvals and Shares Drop? That's Biotech!
• How Many Pharmas Does It Take to Accelerate Drug Development?
• EU Approval? Fat Chance!
• If You Can't Beat 'Em, Find an Indication Where They Failed
• FDA Makes This Biotech Less Risky
• A Potential 36-Bagger Biotech
• Is This Good Drug Good Enough?
• Sunshine on the FDA
• Challenges Loom for This New Drug
• Is This Drug Taking on Water?
• What to Make of This FDA Rejection
• Why Risk Is Always Relative in Biotech
• "Better Than Nothing" Doesn't Cut It for Zalicus
• Does This Pharma Deal Make Sense?
• Big Demand for (Free) Obesity Drugs
• Is This Biotech's Shortened Study Good Enough for Approval?
• A Once-in-a-Blue-Moon FDA Approval
• The Biggest Little Biotechs in the World
• Converting the Dissatisfied
• A Good Start on the Biosimilar Front
• Reading Between the FDA Lines
• This Dividend Stock Needs a Hit, but This Isn't It
• A Biotech Field of Dreams?
• Do We Really Need Another Injected Rheumatoid Arthritis Drug?
• The Most Epic Drug Failure. Ever.
• Like a Sumo Wrestler, Pfizer Goes Big, With Help
• We're Shrinking; It Could Be Worse
• Orange Book Blues
• Guilt by Association = 30% Slaughter?
• Let's Only Sell High-Growth Drugs
• 3 Things to Watch at Dendreon
• 3 Companies Experiencing the Post-Approval Blues
• Pfizer Bulks Up Before the Breakup
• A Growth-Free Quarter -- and That's OK
• A Spectrum of Valuations
• It's Full Speed Ahead for This Biotech
• The Winner of the Bapi Failure
• 3 Drugs Approved, but Only 1 Matters